Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tarsus Pharmaceuticals, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.34 · Expires 2036-06-24 | Direct | 3,837 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 3,837 · Balance 3,837 F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,417 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 2,417 · Balance 2,417 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,417 | $0.00 | $0.00 |
DisclosureSEC source: 0002044770-26-000008 · wk-form4_1782765122.xml · derivative · entry 2 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,417 Underlying: Common Stock · 2,417 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 3,837 | $0.00 Strike: $64.34 | $0.00 |
DisclosureSEC source: 0002044770-26-000008 · wk-form4_1782765122.xml · derivative · entry 1 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires 2036-06-24 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:17 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,954 | $62.08 | $183,384.32 |
DisclosureSEC source: 0002044770-26-000006 · wk-form4_1781727435.xml · nonDerivative · entry 1 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,233 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0002044770-26-000004 · wk-form4_1781640353.xml · derivative · entry 2 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002044770-26-000004 · wk-form4_1781640353.xml · nonDerivative · entry 1 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 15, 2025 Filed Jan 15, 2026 00:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionRestricted Stock Units · Derivative | 2,233 | $0.00 | $0.00 |
DisclosureSEC source: 0002044770-26-000002 · wk-form4_1768437158.xml · derivative · entry 2 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,467 Underlying: Common Stock · 2,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs will vest in three equal installments on December 15th of 2025, 2026 and 2027, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in three equal installments on December 15th of 2025, 2026 and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| December 15, 2025 Filed Jan 15, 2026 00:32 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002044770-26-000002 · wk-form4_1768437158.xml · nonDerivative · entry 1 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 2,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-25-000093 · wk-form4_1750104304.xml · derivative · entry 2 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,954 Underlying: Common Stock · 2,954 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 4,540 | $0.00 Strike: $40.95 | $0.00 |
DisclosureSEC source: 0001819790-25-000093 · wk-form4_1750104304.xml · derivative · entry 1 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,540 Underlying: Common Stock · 4,540 shares Expires 2035-06-11 F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:37 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantRestricted Stock Units · Derivative | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001819790-24-000135 · wk-form4_1731706621.xml · derivative · entry 2 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: The RSUs will vest in three equal annual installments on December 15th of each of 2025, 2026, and 2027, subject to the Reporting Person's continuous service. F3 · derivative.expiration_date: The RSUs will vest in three equal annual installments on December 15th of each of 2025, 2026, and 2027, subject to the Reporting Person's continuous service. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:37 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $46.51 | $0.00 |
DisclosureSEC source: 0001819790-24-000135 · wk-form4_1731706621.xml · derivative · entry 1 Goodrich Katherine · CIK 0002044770 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-11-12 F1 · derivative.exercise_date: The option shares will vest in three equal annual installments beginning on November 13, 2025, subject to the Reporting Person's continuous service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.